347850 — DND Pharmatech Income Statement
0.000.00%
Last trade - 00:00- KR₩322bn
- KR₩323bn
- KR₩19bn
Annual income statement for DND Pharmatech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 1,364 | 611 | 18,677 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 69,107 | 77,041 | 188,985 | 27,582 |
| Operating Profit | -69,107 | -75,677 | -188,375 | -8,904 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -66,995 | -72,047 | -163,513 | 4,494 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -64,284 | -69,862 | -137,025 | 3,427 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -63,406 | -68,224 | -136,067 | 3,934 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | -63,406 | -68,224 | -136,067 | -10,353 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -6,080 | -6,542 | -6,926 | -1,273 |
| Dividends per Share |